trending Market Intelligence /marketintelligence/en/news-insights/trending/vSnt-bCnYyuYiN3dT2E2aQ2 content esgSubNav
In This List

China FDA grants priority review to Eisai's Lenvima for liver cancer

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Insight Weekly: Labor market struggles; solar demand remains strong; banks' deposit holdings


China FDA grants priority review to Eisai's Lenvima for liver cancer

The China Food and Drug Administration granted priority review and approval status to Eisai Co. Ltd.'s Lenvima to treat hepatocellular carcinoma, a type of liver cancer.

The regulator implemented the priority review and approval status in February 2016 to shorten the drug approval process.

Lenvima, also known as Kisplyx or lenvatinib, is currently approved for refractory thyroid cancer in over 50 countries.

The company has submitted applications for an additional indication for Lenvima for the treatment of hepatocellular carcinoma in the U.S., Europe, China, Taiwan and Japan.